The chapter explores how AI and cloud computing have revolutionized drug discovery, focusing on companies like Recursion, Accenture, and Benevolent AI accelerating the development of successful candidates for clinical trials. It delves into the interaction between big pharma and AI-based biotechs, discussing licensing AI techniques to speed up drug development processes. The use of generative AI in predicting compound binding, protein folding, and medical image analysis is highlighted, along with the challenges of obtaining high-quality data and the importance of human involvement in fine-tuning AI models.